After two years in the shadows, health stocks are back as a haven for investors navigating economic uncertainty.

Eli Lilly (NYSE:LLY) shares soar, driven by strong growth in weight-loss drugs, major investments, and bullish analyst ratings.

Investors who backed technology companies around the world five years ago would have seen average returns of more than 20 per ...

Eli Lilly & Co. said Tuesday it's cutting the price of single-dose vials of its Zepbound treatment for diabetes and obesity for patients who have to pay for the drug themselves. It said it will also ...

Eli Lilly stock surges past $840, outperforming the S&P 500. Click here to learn why LLY stock is still undervalued and why ...

Eli Lilly (LLY) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over ...

Eli Lilly’s stock price fell to $872.91. Shareholders have lost 8.3% of their capital, which is disappointing considering the ...

The weakness was also weighing on shares of some of Walmart's rivals, as Costco Wholesale Corp.'s stock (COST) fell 2.2% and Target Corp. shares (TGT) shed 1.1%, to underperform the S&P 500 index's ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch Automation brings you the latest, most pertinent content at record speed and with ...

For years, Eli Lilly has been generating solid growth ... the stock to rise less than 30% from where it is right now. Lilly's P/E ratio may appear high now. But as the company scales up its ...